Indivior PLC Ordinary Shares (INDV) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Indivior PLC Ordinary Shares stock (INDV) is currently trading at $30.26. Indivior PLC Ordinary Shares PE ratio is 17.87. Indivior PLC Ordinary Shares PS ratio (Price-to-Sales) is 2.96. Analyst consensus price target for INDV is $46.86. WallStSmart rates INDV as Hold.
- INDV PE ratio analysis and historical PE chart
- INDV PS ratio (Price-to-Sales) history and trend
- INDV intrinsic value — DCF, Graham Number, EPV models
- INDV stock price prediction 2025 2026 2027 2028 2029 2030
- INDV fair value vs current price
- INDV insider transactions and insider buying
- Is INDV undervalued or overvalued?
- Indivior PLC Ordinary Shares financial analysis — revenue, earnings, cash flow
- INDV Piotroski F-Score and Altman Z-Score
- INDV analyst price target and Smart Rating
Indivior
📊 No data available
Try selecting a different time range
INDV Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Indivior PLC Ordinary Shares (INDV)
INDV trades at a significant discount to its Graham intrinsic value of $76.75, offering a 56% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Indivior PLC Ordinary Shares (INDV) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, eps growth, profit margin. Concerns around price/book. Fundamentals are solid but monitor weak areas for improvement.
Indivior PLC Ordinary Shares (INDV) Key Strengths (5)
Keeps $37 of every $100 in revenue after operating costs
Earnings per share surging 376.20% year-over-year
86.45% of shares held by major funds and institutions
Strong profitability: $17 kept per $100 revenue
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Indivior PLC Ordinary Shares (INDV) Areas to Watch (4)
Very expensive at 145.3x book value
Moderate profitability with room for improvement
Revenue is fairly priced at 2.96x sales
Solid revenue growth at 19.70% per year
Indivior PLC Ordinary Shares (INDV) Detailed Analysis Report
Overall Assessment
This company scores 62/100 in our Smart Analysis, earning a C+ grade. Out of 9 metrics analyzed, 5 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 4.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, EPS Growth, Institutional Own.. Profitability is solid with Operating Margin at 37.10%, Profit Margin at 17.00%. Growth metrics are encouraging with EPS Growth at 376.20%.
The Bear Case
The primary concerns are Price/Book, Return on Equity, Price/Sales. Some valuation metrics including Price/Sales (2.96), Price/Book (145.25) suggest expensive pricing. Growth concerns include Revenue Growth at 19.70%, which may limit upside. Profitability pressure is visible in Return on Equity at 12.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 12.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 19.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Operating Margin, EPS Growth) and negatives (Price/Book, Return on Equity). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
INDV Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
INDV's Price-to-Sales ratio of 2.96x trades 144% above its historical average of 1.21x (84th percentile), historically expensive. The current valuation is 22% below its historical high of 3.81x set in Dec 2025, and 4126% above its historical low of 0.07x in Jun 2019. Over the past 12 months, the PS ratio has expanded from ~1.0x, reflecting growing market expectations outpacing revenue growth.
Compare INDV with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Indivior PLC Ordinary Shares (INDV) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Indivior PLC Ordinary Shares is a strong growth company balancing expansion with improving profitability. Revenue reached 1.2B with 20% growth year-over-year. Profit margins of 17.0% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 1220.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -245M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Indivior PLC Ordinary Shares.
Bottom Line
Indivior PLC Ordinary Shares offers an attractive blend of growth (20% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Indivior PLC Ordinary Shares(INDV)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.